Selected research
Industry Research
Insulin Degludec and Insulin Aspart Injection Industry Research Report 2026
Market perspective
The global Insulin Degludec and Insulin Aspart Injection market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Insulin Degludec and Insulin Aspart Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Insulin Degludec and Insulin Aspart Injection is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Insulin Degludec and Insulin Aspart Injection is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Insulin Degludec and Insulin Aspart Injection include Sihuan Pharmaceutical Holdings Group and Novo Nordisk A/S among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Insulin Degludec and Insulin Aspart Injection market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Insulin Degludec and Insulin Aspart Injection Market by Company
Sihuan Pharmaceutical Holdings Group
Novo Nordisk A/S
Insulin Degludec and Insulin Aspart Injection Segment by Type
Long-acting Insulin
Rapid-acting Insulin
Insulin Degludec and Insulin Aspart Injection Segment by Application
Clinic
Hospital
Others
Insulin Degludec and Insulin Aspart Injection Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Insulin Degludec and Insulin Aspart Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Insulin Degludec and Insulin Aspart Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Insulin Degludec and Insulin Aspart Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Insulin Degludec and Insulin Aspart Injection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Insulin Degludec and Insulin Aspart Injection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Insulin Degludec and Insulin Aspart Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Long-acting Insulin
- Rapid-acting Insulin
Applications
- Clinic
- Hospital
- Others
Companies covered
- Sihuan Pharmaceutical Holdings Group
- Novo Nordisk A/S
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Insulin Degludec and Insulin Aspart Injection Market Size (2021-2032)
- 2.2.2 Global Insulin Degludec and Insulin Aspart Injection Sales (2021-2032)
- 2.2.3 Global Insulin Degludec and Insulin Aspart Injection Market Average Price (2021-2032)
- 2.3 Insulin Degludec and Insulin Aspart Injection by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Long-acting Insulin
- 2.3.3 Rapid-acting Insulin
- 2.4 Insulin Degludec and Insulin Aspart Injection by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Clinic
- 2.4.3 Hospital
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Insulin Degludec and Insulin Aspart Injection Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Insulin Degludec and Insulin Aspart Injection Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Insulin Degludec and Insulin Aspart Injection Revenue of Manufacturers (2021-2026)
- 3.4 Global Insulin Degludec and Insulin Aspart Injection Average Price by Manufacturers (2021-2026)
- 3.5 Global Insulin Degludec and Insulin Aspart Injection Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Insulin Degludec and Insulin Aspart Injection, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Insulin Degludec and Insulin Aspart Injection, Product Type & Application
- 3.8 Global Manufacturers of Insulin Degludec and Insulin Aspart Injection, Established Date
- 3.9 Global Insulin Degludec and Insulin Aspart Injection Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sihuan Pharmaceutical Holdings Group
- 4.1.1 Sihuan Pharmaceutical Holdings Group Company Information
- 4.1.2 Sihuan Pharmaceutical Holdings Group Business Overview
- 4.1.3 Sihuan Pharmaceutical Holdings Group Insulin Degludec and Insulin Aspart Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sihuan Pharmaceutical Holdings Group Insulin Degludec and Insulin Aspart Injection Product Portfolio
- 4.1.5 Sihuan Pharmaceutical Holdings Group Recent Developments
- 4.2 Novo Nordisk A/S
- 4.2.1 Novo Nordisk A/S Company Information
- 4.2.2 Novo Nordisk A/S Business Overview
- 4.2.3 Novo Nordisk A/S Insulin Degludec and Insulin Aspart Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novo Nordisk A/S Insulin Degludec and Insulin Aspart Injection Product Portfolio
- 4.2.5 Novo Nordisk A/S Recent Developments
5 Global Insulin Degludec and Insulin Aspart Injection Market Scenario by Region
- 5.1 Global Insulin Degludec and Insulin Aspart Injection Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Insulin Degludec and Insulin Aspart Injection Sales by Region: 2021-2032
- 5.2.1 Global Insulin Degludec and Insulin Aspart Injection Sales by Region: 2021-2026
- 5.2.2 Global Insulin Degludec and Insulin Aspart Injection Sales by Region: 2027-2032
- 5.3 Global Insulin Degludec and Insulin Aspart Injection Revenue by Region: 2021-2032
- 5.3.1 Global Insulin Degludec and Insulin Aspart Injection Revenue by Region: 2021-2026
- 5.3.2 Global Insulin Degludec and Insulin Aspart Injection Revenue by Region: 2027-2032
- 5.4 North America Insulin Degludec and Insulin Aspart Injection Market Facts & Figures by Country
- 5.4.1 North America Insulin Degludec and Insulin Aspart Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Insulin Degludec and Insulin Aspart Injection Sales by Country (2021-2032)
- 5.4.3 North America Insulin Degludec and Insulin Aspart Injection Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Insulin Degludec and Insulin Aspart Injection Market Facts & Figures by Country
- 5.5.1 Europe Insulin Degludec and Insulin Aspart Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Insulin Degludec and Insulin Aspart Injection Sales by Country (2021-2032)
- 5.5.3 Europe Insulin Degludec and Insulin Aspart Injection Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Insulin Degludec and Insulin Aspart Injection Market Facts & Figures by Country
- 5.6.1 Asia Pacific Insulin Degludec and Insulin Aspart Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Insulin Degludec and Insulin Aspart Injection Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Insulin Degludec and Insulin Aspart Injection Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Insulin Degludec and Insulin Aspart Injection Market Facts & Figures by Country
- 5.7.1 South America Insulin Degludec and Insulin Aspart Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Insulin Degludec and Insulin Aspart Injection Sales by Country (2021-2032)
- 5.7.3 South America Insulin Degludec and Insulin Aspart Injection Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Insulin Degludec and Insulin Aspart Injection Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Insulin Degludec and Insulin Aspart Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Insulin Degludec and Insulin Aspart Injection Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Insulin Degludec and Insulin Aspart Injection Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Insulin Degludec and Insulin Aspart Injection Sales by Type (2021-2032)
- 6.1.1 Global Insulin Degludec and Insulin Aspart Injection Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Insulin Degludec and Insulin Aspart Injection Sales Market Share by Type (2021-2032)
- 6.2 Global Insulin Degludec and Insulin Aspart Injection Revenue by Type (2021-2032)
- 6.2.1 Global Insulin Degludec and Insulin Aspart Injection Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Insulin Degludec and Insulin Aspart Injection Revenue Market Share by Type (2021-2032)
- 6.3 Global Insulin Degludec and Insulin Aspart Injection Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Insulin Degludec and Insulin Aspart Injection Sales by Application (2021-2032)
- 7.1.1 Global Insulin Degludec and Insulin Aspart Injection Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Insulin Degludec and Insulin Aspart Injection Sales Market Share by Application (2021-2032)
- 7.2 Global Insulin Degludec and Insulin Aspart Injection Revenue by Application (2021-2032)
- 7.2.1 Global Insulin Degludec and Insulin Aspart Injection Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Insulin Degludec and Insulin Aspart Injection Revenue Market Share by Application (2021-2032)
- 7.3 Global Insulin Degludec and Insulin Aspart Injection Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Insulin Degludec and Insulin Aspart Injection Value Chain Analysis
- 8.1.1 Insulin Degludec and Insulin Aspart Injection Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Insulin Degludec and Insulin Aspart Injection Production Mode & Process
- 8.2 Insulin Degludec and Insulin Aspart Injection Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Insulin Degludec and Insulin Aspart Injection Distributors
- 8.2.3 Insulin Degludec and Insulin Aspart Injection Customers
9 Global Insulin Degludec and Insulin Aspart Injection Analyzing Market Dynamics
- 9.1 Insulin Degludec and Insulin Aspart Injection Industry Trends
- 9.2 Insulin Degludec and Insulin Aspart Injection Industry Drivers
- 9.3 Insulin Degludec and Insulin Aspart Injection Industry Opportunities and Challenges
- 9.4 Insulin Degludec and Insulin Aspart Injection Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst